Throughout her distinguished career, Dr. Reiersen has been involved in numerous research projects on genetic causes and life course of neurodevelopmental and psychiatric conditions.
SAINT LOUIS, MO, March 01, 2024 /24-7PressRelease/ -- Angela M. Reiersen, MD, has been included in Marquis Who's Who. As in all Marquis Who's Who biographical volumes, individuals profiled are selected on the basis of current reference value. Factors such as position, noteworthy accomplishments, visibility, and prominence in a field are all taken into account during the selection process.
Dr. Reiersen is recognized for her expertise in psychiatry and research and for being a faculty member at Washington University in Saint Louis for over 15 years. She joined the institution in 1999 as a psychiatry trainee and rose to become an associate professor of psychiatry, where she has influenced the lives of many medical students and post-graduate clinical and research trainees. Dr. Reiersen directs the First Contact Assessment Service, which specializes in providing neurological and psychiatric assessment of patients with neurodevelopmental disorders, genetic conditions, and/or risk for severe mental illness. Additionally, she is affiliated with Saint Louis Children's Hospital.
Throughout her distinguished career, Dr. Reiersen has been involved in numerous research projects on genetic causes and life course of neurodevelopmental and psychiatric conditions. She has been a co-investigator on a longitudinal study of people with Wolfram syndrome, a rare genetic condition that affects cellular stress responses. Dr. Reiersen is perhaps most known for her discovery that fluvoxamine, a psychiatric drug with anti-inflammatory effects through activation of the sigma1 receptor, can reduce the risk of clinical deterioration in patients with acute COVID-19 illness. Her initial work in this area has been confirmed in multiple randomized clinical trials throughout the world. Her efforts have proven fruitful, and her work has been recognized worldwide for using this inexpensive drug, which is available in generic form in most parts of the world. She is presently conducting a trial of fluvoxamine for treatment of long COVID and hopes to also test other drugs—including combination therapies—for this condition.
As a seasoned researcher, Dr. Reiersen has contributed numerous articles to scholarly journals and been invited to write multiple book chapters. She has also served in various editorial roles for the Journal of the American Academy of Child and Adolescent Psychiatry, the Journal of Abnormal Psychology, and the Scandinavian Journal of Child and Adolescent Psychiatry and Psychology. Moreover, Dr. Reiersen has lectured at numerous national and international scientific meetings and as an invited speaker at multiple universities.
In preparation for her medical career, Dr. Reiersen received a Bachelor of Science in biology from the University of California Davis in 1994 and a Doctor of Medicine from the University of Southern California in 1999. She also completed a residency in general psychiatry, a clinical fellowship in child and adolescent psychiatry, where she rose to chief fellow, and a postdoctoral research fellowship in psychiatric epidemiology and biostatistics at Washington University. Moreover, she garnered a Master of Psychiatric Epidemiology degree from Washington University in 2006. Dr. Reiersen is licensed to practice medicine in Missouri and is board-certified in psychiatry and child and adolescent psychiatry.
As part of her ongoing professional commitments, Dr. Reiersen is a member of the American Academy of Child and Adolescent Psychiatry. She was recognized for excellence in clinical psychiatry, teaching, and research with an Eli Robins Award in 2004, was given an Academic Women's Network Student Leadership Award in 2006, received several awards for her scientific review and editorial efforts at the Journal of the American Academy of Child and Adolescent Psychiatry between 2018 and 2023, and won a Dean's Impact Award from Washington University in 2023, which recognized her superior efforts in response to the COVID-19 pandemic. Apart from her accolades, Dr. Reiersen has appeared on the "Get the Stuck Out" and "COVID Unfiltered" podcasts and on CBS's "60 Minutes" and has been quoted in many news articles related to clinical trials of fluvoxamine for COVID-19. She credits her professional accomplishments to the invaluable mentorship she has received throughout her career.
About Marquis Who's Who®:
Since 1899, when A. N. Marquis printed the First Edition of Who's Who in America®, Marquis Who's Who® has chronicled the lives of the most accomplished individuals and innovators from every significant field of endeavor, including politics, business, medicine, law, education, art, religion and entertainment. Marquis celebrates its 125th anniversary in 2023, and Who's Who in America® remains an essential biographical source for thousands of researchers, journalists, librarians and executive search firms around the world. Marquis® publications may be visited at the official Marquis Who's Who® website at www.marquiswhoswho.com.
# # #